Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Publication year range
1.
Life Sci ; 93(12-14): 471-7, 2013 Oct 06.
Article in English | MEDLINE | ID: mdl-23988851

ABSTRACT

AIM: The anti-inflammatory effects of exogenous opioid compounds have been demonstrated in several conditions. Nevertheless, the function of endogenous opioid peptides released by the host during inflammatory processes deserves further characterization. The aim of this study was to verify whether endogenous opioids are involved in the progression of the inflammatory alveolar bone loss induced by ligature in rats. MAIN METHODS: The experimental model of periodontal disease (PD) induced by ligature in rats was used throughout the study. A silk ligature was placed around the 2nd upper molar of male Holtzman rats, for 7 days. Rats received different doses of either the non-selective opioid antagonist naloxone or vehicle, locally into the afflicted gingival tissue, from the 3rd to the 5th day after ligature placement. In the 7th experimental day, rats were euthanized and their maxillae were collected for evaluation of alveolar bone and fiber attachment loss, presence of neutrophils (myeloperoxidase assay), osteoclast amount, and levels of cytokines IL-6, TNF-α, IL-8 and IL-10 in periodontal tissues. KEY FINDINGS: Naloxone increased alveolar bone loss significantly, in a dose-dependent manner, in relation to vehicle-treated rats. In contrast, the opioid antagonist did not affect the loss of fiber attachment. The treatment with naloxone also induced a significant increase in myeloperoxidase levels, osteoclast number and cytokines in periodontal tissues of rats with ligature-induced PD. SIGNIFICANCE: Endogenous opioids protect the host from the progression of inflammatory alveolar bone loss that occurs in chronic periodontitis.


Subject(s)
Alveolar Bone Loss/metabolism , Opioid Peptides/physiology , Periodontal Diseases/metabolism , Alveolar Bone Loss/etiology , Alveolar Bone Loss/pathology , Animals , Cytokines/metabolism , Gingiva/metabolism , Gingiva/pathology , Male , Maxillary Diseases/etiology , Maxillary Diseases/metabolism , Maxillary Diseases/pathology , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Osteoclasts/drug effects , Osteoclasts/pathology , Periodontal Diseases/complications , Periodontal Diseases/pathology , Rats , Rats, Sprague-Dawley
2.
Arch Oral Biol ; 56(11): 1256-63, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21683340

ABSTRACT

OBJECTIVE: Receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) are members of the superfamily of ligands and receptors of tumour necrosis factor family involved in bone metabolism. The formation, differentiation and activity of osteoclasts are regulated by these proteins. To clarify the roles of osteoclast regulatory factors in cystic expansion of odontogenic cysts, expression of these proteins were analysed in radicular and dentigerous cysts. DESIGN: The immunohistochemistry expression of these biomarkers were evaluated and measured in lining epithelium and fibrous capsule of the radicular (n=20) and dentigerous cysts (n=20). RESULTS: A similar expression in lining epithelium was observed in the lesions. The fibrous capsule of dentigerous cyst showed a higher content of RANK-positive and RANKL-positive cells than fibrous capsule of radicular cyst. In the lining epithelium the RANKL/OPG ratio showed higher numbers of OPG-positive than RANKL-positive cells, whereas fibrous capsule of the cysts had a tendency to present a similar expression (OPG=RANKL). CONCLUSION: Ours findings indicate the presence of RANK, RANKL and OPG in cysts. Moreover, increased expression of OPG compared to RANKL in the lining epithelium could contribute to the differential bone resorption activity in theses lesions.


Subject(s)
Dentigerous Cyst/metabolism , Mandibular Diseases/metabolism , Maxillary Diseases/metabolism , Osteoprotegerin/biosynthesis , RANK Ligand/biosynthesis , Radicular Cyst/metabolism , Receptor Activator of Nuclear Factor-kappa B/biosynthesis , Adolescent , Adult , Child , Dentigerous Cyst/genetics , Epithelium/metabolism , Female , Humans , Immunohistochemistry , Male , Mandibular Diseases/genetics , Maxillary Diseases/genetics , Middle Aged , Osteoclasts/metabolism , Radicular Cyst/genetics , Young Adult
3.
Microbes Infect ; 10(5): 489-96, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18403243

ABSTRACT

Inflammatory immune reactions in response to periodontopathogens trigger periodontal destruction, but their role to protect the host against infection remains unknown. Thus, we examined the mechanisms by which IFN-gamma modulates the outcome of Aggregatibacter actinomycetemcomitans-induced periodontal disease in mice. Our results showed that IFN-gamma deficient mice developed less severe periodontitis in response to A. actinomycetemcomitans infection, characterized by significant lower alveolar bone loss and inflammatory reaction. However, the absence of IFN-gamma results in increased bacterial load in periodontal tissues and higher acute phase reaction, followed by a disseminated bacterial infection and mice death during the course of the disease. Such impaired host response was found to be associated with a reduction in the levels of inflammatory cytokines and chemokines and in the number of GR1+, F4/80+, CD4+ and CD8+ leukocytes in the diseased periodontium of IFN-gamma deficient mice. In addition, the levels of both antimicrobial mediators myeloperoxidase and inducible nitric oxide synthase were also found to be reduced in IFN-KO mice. Our results demonstrate for the first time that a periodontal infection may be lethal in an immunocompromised host. In addition, the mechanisms involved in IFN-gamma mediated cell migration to diseased periodontal tissues, and its essential role to control A. actinomycetemcomitans infection were clarified.


Subject(s)
Actinobacillus Infections/immunology , Aggregatibacter actinomycetemcomitans/immunology , Alveolar Bone Loss/immunology , Interferon-gamma/immunology , Maxillary Diseases/immunology , Actinobacillus Infections/metabolism , Acute-Phase Reaction/immunology , Alveolar Bone Loss/metabolism , Alveolar Bone Loss/microbiology , Animals , DNA, Bacterial/isolation & purification , Immunocompromised Host , Inflammation Mediators/analysis , Interferon-gamma/deficiency , Male , Maxillary Diseases/metabolism , Maxillary Diseases/microbiology , Mice , Mice, Inbred C57BL , Mice, Knockout , Nitric Oxide Synthase Type II/analysis , Periodontitis/immunology , Periodontitis/metabolism , Periodontitis/microbiology , Peroxidase/analysis
4.
Oral Oncol ; 40(5): 545-51, 2004 May.
Article in English | MEDLINE | ID: mdl-15006629

ABSTRACT

Central mucoepidermoid carcinoma (MEC) is an entity whose origin is still controversial. Glandular odontogenic cyst (GOC) is a recently described lesion whose relationship to low-grade central MEC has been reported in the literature. Our aim was to assess the cytokeratin (CK) profile of central MEC and GOC, and compare the results with CK expression in salivary gland MEC and odontogenic cysts and tumors. Eighty-five cases, including 6 central MECs, 23 salivary gland MECs, 10 GOCs, 34 odontogenic cysts and 12 ameloblastomas, were studied through immunohistochemistry using eleven monoclonal anti-CK antibodies. All central MECs expressed CKs 5, 7, 8, 14, and 18 and all GOCs expressed CKs 5, 7, 8, 13, 14, and 19. Comparing CK expression from GOC and central MEC we found differences in CKs 18 (30% vs 100%) and 19 (100% vs 50%). Central MEC and GOC are probably distinct entities with CK profiles similar to lesions of glandular and odontogenic origins, respectively, and expression of CKs 18 and 19 could be useful in their differential diagnosis.


Subject(s)
Carcinoma, Mucoepidermoid/chemistry , Jaw Diseases/metabolism , Keratins/analysis , Odontogenic Cysts/chemistry , Salivary Gland Neoplasms/chemistry , Adult , Aged , Carcinoma, Mucoepidermoid/pathology , Female , Humans , Immunohistochemistry/methods , Jaw Diseases/pathology , Male , Mandibular Diseases/metabolism , Mandibular Diseases/pathology , Maxillary Diseases/metabolism , Maxillary Diseases/pathology , Middle Aged , Odontogenic Cysts/pathology , Salivary Gland Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL